Endo International (NASDAQ:ENDP) (TSE:ENL) announced its earnings results on Tuesday. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.12, MarketWatch Earnings reports. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The company had revenue of $700.53 million for the quarter, compared to the consensus estimate of $691.94 million. During the same period last year, the business posted $1.23 EPS. The company’s revenue was down 32.5% on a year-over-year basis. Endo International updated its FY18 guidance to $2.15-2.55 EPS.
Shares of ENDP traded up $0.21 during mid-day trading on Tuesday, hitting $5.84. The company’s stock had a trading volume of 4,170,474 shares, compared to its average volume of 5,363,247. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.02 and a quick ratio of 0.85. The stock has a market capitalization of $1.25 billion, a P/E ratio of 1.52 and a beta of 0.34. Endo International has a 1-year low of $5.27 and a 1-year high of $14.15.
Several research analysts have weighed in on the company. ValuEngine downgraded Endo International from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research upgraded Endo International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 1st. BidaskClub downgraded Endo International from a “sell” rating to a “strong sell” rating in a research note on Friday, April 6th. Mizuho downgraded Endo International from a “buy” rating to a “neutral” rating and lowered their target price for the company from $12.00 to $7.00 in a research note on Wednesday, April 4th. Finally, Barclays set a $9.00 target price on Endo International and gave the company a “hold” rating in a research note on Saturday, March 10th. Three research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.40.
Institutional investors and hedge funds have recently bought and sold shares of the company. Diamond Hill Capital Management Inc. raised its holdings in Endo International by 9.8% during the first quarter. Diamond Hill Capital Management Inc. now owns 1,089,659 shares of the company’s stock worth $6,473,000 after purchasing an additional 96,990 shares during the last quarter. River & Mercantile Asset Management LLP raised its holdings in Endo International by 32.7% during the fourth quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock worth $3,679,000 after purchasing an additional 117,110 shares during the last quarter. Alps Advisors Inc. raised its holdings in Endo International by 48.8% during the first quarter. Alps Advisors Inc. now owns 457,917 shares of the company’s stock worth $2,720,000 after purchasing an additional 150,078 shares during the last quarter. UBS Asset Management Americas Inc. raised its holdings in Endo International by 4.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock worth $1,720,000 after purchasing an additional 9,438 shares during the last quarter. Finally, Quantitative Investment Management LLC acquired a new position in Endo International during the fourth quarter worth $1,569,000. 93.82% of the stock is owned by institutional investors and hedge funds.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.